Biosimilar SB12 demonstrated comparable efficacy and safety for paroxysmal nocturnal hemoglobinuria (PNH) to its reference drug, showing similar outcomes across diverse patient groups.

Explore the latest advancements in rheumatology biosimilars, including FDA approvals, patient switching trends, and ...

To read all of these articles and more, visit centerforbiosimilars.com.

Josh Canavan, PharmD, head of pharmacy at RazorMetrics, and Chris O'Dell, senior vice president of market solutions at Turquoise Health, discuss how the health care system must overcome patient ...